Pharmacist

FDB Vela™ Leader to Share Vision for Vastly Reducing Fill Times for Specialty Drug ePrescribing at NCPDP Annual Conference

Retrieved on: 
Thursday, May 4, 2023
Well, Pharmacy technician, Electronic prescribing, Doctor of Pharmacy, Pharmacy, The Westin Kierland Resort & Spa, Convention, Drug utilization review, Innovation, First Databank, MBA, FDB, Bigler, Accreditation Council for Pharmacy Education, Pharmacist, Patel, DUR, NCPDP, ACPE, National Primate Research Exhibition Hall, Patient, Navigo card, Great race, Frustration, Accreditation, Accreditation Council, HL7, Health, Conference, CPE, Safety, Meeting, Nursing

SOUTH SAN FRANCISCO, Calif., May 4, 2023 /PRNewswire/ -- FDB (First Databank, Inc.), the leading provider of drug knowledge that helps healthcare professionals make precise decisions, announced today that Lathe Bigler, vice president of clinical network services for FDB Vela™, will share insights at the NCPDP 2023 Annual Technology & Business Conference on how prescribers can quickly and simply electronically prescribe specialty medications based on new standards, processes, and tools to reduce fill time from weeks to hours (in many cases) and give patients greater access to care.

Key Points: 
  • Recently celebrating its first anniversary, FDB Vela empowers innovation, reduces barriers to participation, and increases the cost-effectiveness of electronic prescribing.
  • These advances help close gaps in care in the specialty medication process while improving prescriber efficiency, increasing patient adherence, and reducing frustration for all involved.
  • Bigler continued, "The hurdles involved in the current state of specialty drug prescribing cause widespread dissatisfaction among stakeholders.
  • Also speaking at the NCPDP 2023 Annual Technology & Business Conference will be Chirag Patel, PharmD, MBA, senior product manager for FDB.

Drug Store News Awards OmniSYS for Technology and Automation Innovation Excellence

Retrieved on: 
Thursday, May 4, 2023
Apps, Applications, Technology, Health Technology, Telemedicine, Virtual Medicine, Software, Managed Care, Health, Pharmaceutical, Data Management, IVR, Doctor of Pharmacy, Workflow, DME, Pharmacy, Multimedia, Pharmacist, Documentation, Patient, API, News, Behavior, Automation, Health insurance, Health care

View the full release here: https://www.businesswire.com/news/home/20230504005488/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230504005488/en/
    “OmniSYS continues to be an industry leader in pharmacy technology and automation, consistently delivering efficiencies in workflow and billing to optimize patient care and profitability,” said Sandra Levy, senior editor of Drug Store News.
  • “In a highly competitive market, OmniSYS stands out as a shining star of technology innovation and service excellence.” (Graphic: Business Wire)
    “OmniSYS continues to be an industry leader in pharmacy technology and automation, consistently delivering efficiencies in workflow and billing to optimize patient care and profitability,” said Sandra Levy, senior editor of Drug Store News.
  • “In a highly competitive market, OmniSYS stands out as a shining star of technology innovation and service excellence.”
    OmniSYS’s workflow enabled technology solutions deliver a high level of simplicity and interoperability that allow pharmacies to grow revenue and reduce operational costs.
  • Multichannel patient engagement allows pharmacies to deliver to patients personalized clinical, health and adherence information that can influence behavior and improve health outcomes.

AmerisourceBergen Announces Pharmacy Telehealth Partnership with SteadyMD

Retrieved on: 
Thursday, May 4, 2023
Health, Infectious Diseases, Telemedicine, Virtual Medicine, Health Technology, Managed Care, General Health, Pharmaceutical, Infection, Partnership, Senior, Pharmacy, COVID-19, COVID-19 testing, Thought, Organization, Good Neighbor Pharmacy, Pharmacist, Patient, SVP, Nursing, Pharmaceutical industry, AmerisourceBergen, Test

AmerisourceBergen (AB), a global healthcare company, has announced a strategic partnership with SteadyMD, a B2B telehealth infrastructure provider that powers high-quality telehealth patient experiences for leaders and innovators in healthcare.

Key Points: 
  • AmerisourceBergen (AB), a global healthcare company, has announced a strategic partnership with SteadyMD, a B2B telehealth infrastructure provider that powers high-quality telehealth patient experiences for leaders and innovators in healthcare.
  • With its telehealth solution, AmerisourceBergen is evaluating the long-term viability of the Test to Treat model for use cases, beyond COVID-19, to improve access to treatment.
  • "We're excited to embark on a commercial partnership with AmerisourceBergen and welcome the company to our supportive family of investors," said Guy Friedman, CEO of SteadyMD.
  • In addition to the commercial partnership, AmerisourceBergen has also made an investment in SteadyMD through its venture fund AB Health Ventures.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Tupperware, Rite Aid, and Dish and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, May 4, 2023
Controlled Substances Act, P.C, Tupperware, Shareholder, RAD, Information technology, Pay television, Bank statement, Rite Aid, DISH, Oxycodone, United States Department of Justice, Ground substance, Tupperware Brands, Prescription, False Claims Act, Pharmacist, Dish Network, Annual report, Risk, Fentanyl, News, NYSE, Wireless, Holding company, Audit, Dish

When the true details entered the market, the lawsuit claims that investors suffered damages.

Key Points: 
  • When the true details entered the market, the lawsuit claims that investors suffered damages.
  • For more information on the Rite Aid class action go to: https://bespc.com/cases/RAD
    Dish, together with its subsidiaries, provides pay-TV services in the United States.
  • Throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.
  • For more information on the Dish class action go to: https://bespc.com/cases/DISH

RAD SHAREHOLDER ALERT: Jakubowitz Law Reminds Rite Aid Shareholders of a Lead Plaintiff Deadline of May 19, 2023

Retrieved on: 
Wednesday, May 3, 2023
Controlled Substances Act, Complaint, Oxycodone, United States Department of Justice, Ground substance, Pharmacist, Prescription, Fentanyl, False Claims Act, NYSE, Rite Aid, Risk, Pharmaceutical industry

NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Rite Aid Corporation (NYSE: RAD).

Key Points: 
  • NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Rite Aid Corporation (NYSE: RAD).
  • To receive updates on the lawsuit, fill out the form:
    The lawsuit seeks to recover losses for shareholders who purchased Rite Aid between April 26, 2018 and March 13, 2023.
  • Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until May 19, 2023 to petition the court.
  • Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud.

Option Care Health and Amedisys to Combine Creating a Leading, Independent Platform for Home and Alternate Site Care

Retrieved on: 
Wednesday, May 3, 2023
Communication, McDermott Will & Emery, Social, Patient, Automotive Supplier Innovation Program, Earnings growth, Guggenheim Partners, JOINT, Broad, Ageing, End-of-life care, Goldman Sachs, Organization, Creation, Protocol, Health, Conference, Kirkland & Ellis, Employee Retirement Income Security Act of 1974, Record, Finance, Government, Webcast, Growth, Form, CFO, Adjustment, IR, Sale, Pharmacist, Prospectus, EBITDA, OPCH, Community, Paul, Weiss, Rifkind, Wharton & Garrison, Pharmacy technician, Health insurance, Health care, Cryptocurrency, Nursing, Payment, Amedisys

Upon closing Option Care Health stockholders will own approximately 64.5% of the combined company, and Amedisys stockholders will own approximately 35.5%.

Key Points: 
  • Upon closing Option Care Health stockholders will own approximately 64.5% of the combined company, and Amedisys stockholders will own approximately 35.5%.
  • Combining Amedisys' home health, hospice, palliative, and high-acuity care services with Option Care Health's complementary home and alternate site infusion services will create a leading, independent platform for home and alternate site care.
  • As a leader in home health services, Amedisys adds a strong presence in hospital at home, home health, hospice, palliative, and high-acuity care services better enabling Option Care Health to expand beyond its existing home and alternate site infusion services.
  • In connection with the proposed transaction, Option Care Health and Amedisys will file relevant materials with the United States Securities and Exchange Commission (the "SEC"), including an Option Care Health registration statement on Form S-4 that will include a joint proxy statement of Option Care Health and Amedisys that also constitutes a prospectus of Option Care Health, and a definitive joint proxy statement/prospectus will be mailed to stockholders of Option Care Health and Amedisys.

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Rite Aid Corporation Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm - RAD

Retrieved on: 
Wednesday, May 3, 2023
Titan, Controlled Substances Act, RAD, Rite Aid, Class, Oxycodone, DOJ, United States Department of Justice, Ground substance, Prescription, Plaintiff, False Claims Act, Pharmacist, Risk, Advertising, Court, Fentanyl, NYSE, I-Space (Chinese company), Insurance, Tobacco

WHAT TO DO NEXT: To join the Rite Aid class action, go to https://rosenlegal.com/submit-form/?case_id=9388 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Rite Aid class action, go to https://rosenlegal.com/submit-form/?case_id=9388 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

PrescribeIT to be Launched at Jean Coutu and Brunet Affiliated Pharmacies

Retrieved on: 
Wednesday, May 3, 2023
Communication, Partnership, Pharmacy, Prescription, Jean Coutu Group, Pharmacist, Patient, Map, Health, Jean Coutu, Nursing, Brunet

Starting this spring, this agreement will make the service available gradually to more than 560 pharmacies operated by pharmacist owners under the Jean Coutu and Brunet banners across Ontario, New Brunswick and Quebec over the next few months.

Key Points: 
  • Starting this spring, this agreement will make the service available gradually to more than 560 pharmacies operated by pharmacist owners under the Jean Coutu and Brunet banners across Ontario, New Brunswick and Quebec over the next few months.
  • PrescribeIT® enables prescribers to send prescriptions and renewals electronically to a patient's pharmacy of choice, resulting in more efficient patient care and improved communication between clinicians.
  • It will also free up time for pharmacists to spend on patient care and make their communication with prescribers more efficient," said Nathalie Plante, Vice President, Pharmacy and Health Care, Jean Coutu and Brunet.
  • "Jean Coutu and Brunet affiliated pharmacies have deep roots in Quebec and we are thrilled they have partnered with PrescribeIT® to help change how medications are delivered," said Jamie Bruce, Executive Vice President, Infoway.

PCOM Launches Its First Academic Journal, Focusing on Integrated Primary Care

Retrieved on: 
Wednesday, May 3, 2023
Osteopathic medicine in the United States, Internal medicine, Health education, Nursing, Psychology, AUC, Peer review, Pediatrics, Health, Teaching, Author, Private practice, Lent, Pharmacy, Doctor of Philosophy, Social, DO, Pharmacist, Journal, Patient, Physician, Practitioner, School, ABPP, Philadelphia College of Osteopathic Medicine, Integration, Social work, PCOM, Mental health, Management

PHILADELPHIA, May 3, 2023 /PRNewswire/ -- With an emphasis on reaching the entire spectrum of allied health professionals working within primary care, Philadelphia College of Osteopathic Medicine (PCOM) is launching its first peer-reviewed scientific journal, the Journal of Integrated Primary Care (JIPC) .

Key Points: 
  • PHILADELPHIA, May 3, 2023 /PRNewswire/ -- With an emphasis on reaching the entire spectrum of allied health professionals working within primary care, Philadelphia College of Osteopathic Medicine (PCOM) is launching its first peer-reviewed scientific journal, the Journal of Integrated Primary Care (JIPC) .
  • PCOM has launched its first peer-reviewed scientific journal, the Journal of Integrated Primary Care.
  • Covering primary care, internal medicine, family medicine, nursing, behavioral health, pharmacy, physical therapy, pediatrics, health education, healthcare administration and social work, JIPC aims to grow the evidence base related to integrated primary care professional education, practice and intervention.
  • "This combined topic, primary care with integrated care, is rarely considered by scientific journals," said Jay S. Feldstein, DO '81, president and CEO of PCOM.

Fannin Ltd Named Exclusive Distributor in Ireland for MyBio Self Testing Kits

Retrieved on: 
Wednesday, May 3, 2023
Health, Medical Supplies, Medical Devices, Linda, Fannin, Partnership, Ovulation, Pharmacy, International business development, Menopause, Built-in self-test, Woman, LTD, Fertility, Pharmacist, Male, International business, Prostate-specific antigen, Birth control, Pregnancy

Fannin Ltd, Dublin, Ireland announced a strategic partnership with MyBio™, Kilkenny, Ireland aimed at providing the opportunity for people to take more responsibility for their own health.

Key Points: 
  • Fannin Ltd, Dublin, Ireland announced a strategic partnership with MyBio™, Kilkenny, Ireland aimed at providing the opportunity for people to take more responsibility for their own health.
  • Founded in 2009 by Dr Linda Nolan, MyBio™ is a leading supplier of life science, diagnostic, and wellness products.
  • Since 2020, MyBio™ has become a market leader in the supply of antigen self-testing kits across Ireland, the UK and Europe.
  • Patrick Tehan, General Manager of Pharma Ireland: “We are very pleased to be partnering with MyBio™ to bring their range of MyBio™ self-testing kits to retail pharmacies in Ireland.